Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo

被引:42
作者
Oflazoglu, E
Swart, DA
Anders-Bartholo, P
Jessup, HK
Norment, AM
Lawrence, WA
Brasel, K
Tocker, JE
Horan, T
Welcher, AA
Fitzpatrick, DR
机构
[1] Amgen Inc, Immunol Syst, Dept Inflammat, Seattle, WA 98119 USA
[2] Amgen Inc, Dept Med Sci, Seattle, WA 98119 USA
[3] Amgen Inc, Dept Oncol, Seattle, WA 98119 USA
[4] Amgen Inc, Dept Prot Sci, Seattle, WA 98119 USA
关键词
PD-1; PD-L2; Th2; cells; dendritic cells; regulatory T cells;
D O I
10.1002/eji.200425197
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed death-1 ligand 2 (PD-L2) is a ligand for programmed death-1 (PD-1), a receptor that plays an inhibitory role in T cell activation. Since previous studies have shown upregulation of PD-L2 expression by Th2 cytokines, and asthma is driven by a Th2 response, we hypothesized that PD-L2 might be involved in regulation of the immune response in this disease. We have found that lungs from asthmatic mice had sustained up-regulation of PD-1 and PD-L2, with PD-L2 primarily on dendritic cells. Although addition of PD-L2-Fc in vitro led to decreased T cell proliferation and cytokine production, administration of PD-L2-Fc in vivo in a mouse asthma model resulted in elevated serum IgE levels, increased eosinophilic and lymphocytic infiltration into bronchoalveolar lavage fluid, higher number of cells in the draining lymph nodes, and production of IL-5 and IL-13 from these cells. Although PD-1 was expressed on regulatory T cells, PD-L2-Fc did not affect regulatory T cell activity in vitro. This study provides in vivo evidence of an exacerbated inflammatory response following PD-L2-Fc administration and indicates a potential role for this molecule in Th2-mediated diseases such as asthma.
引用
收藏
页码:3326 / 3336
页数:11
相关论文
共 38 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]  
Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745
[3]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[4]   CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].
Chambers, CA ;
Kuhns, MS ;
Egen, JG ;
Allison, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594
[5]  
Cohn L, 1999, J IMMUNOL, V162, P6178
[6]   INTERLEUKIN-4 IS REQUIRED FOR THE INDUCTION OF LUNG TH2 MUCOSAL IMMUNITY [J].
COYLE, AJ ;
LEGROS, G ;
BERTRAND, C ;
TSUYUKI, S ;
HEUSSER, CH ;
KOPF, M ;
ANDERSON, GP .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (01) :54-59
[7]   The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function [J].
Coyle, AJ ;
Gutierrez-Ramos, JC .
NATURE IMMUNOLOGY, 2001, 2 (03) :203-209
[8]  
DECLERCK YA, 1991, J BIOL CHEM, V266, P3893
[9]  
Dong HD, 1999, NAT MED, V5, P1365
[10]   Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model [J].
Foster, PS ;
Hogan, SP ;
Ramsay, AJ ;
Matthaei, KI ;
Young, IG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :195-201